MedWatch

Eli Lilly upgrades full-year guidance due to solid growth in Q1

US-based pharmaceutical firm Eli Lilly has adjusted its revenue projection for the full year, with the new outlook of USD 28.8–29.3bn.

Photo: Mike Segar/Reuters/Ritzau Scanpix

US-based Eli Lilly is upgrading its 2022 revenue outlook in connection with the company’s first quarterly report on Thursday.

The Novo Nordisk rival within the diabetes area is now expecting year-ending revenue to reach USD 28.8–29.3bn. A prior forecast stated USD 27.8–28.3bn, and the upward adjustment therefore surpasses the analyst consensus estimate of USD 28.43bn, which was compiled by Bloomberg News.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs